ZEMPLAR (paricalcitol)
Zemplar is a vitamin D analog used to manage secondary hyperparathyroidism in patients with chronic kidney disease. It helps adults and children aged 10 and older who are in stages 3 or 4 of the disease, as well as those in stage 5 who require dialysis. This medication helps prevent and manage the overproduction of parathyroid hormone that often occurs as kidney function declines.
How ZEMPLAR Works
Paricalcitol works by binding to the vitamin D receptor, which triggers the activation of specific vitamin D responsive pathways. This interaction inhibits the synthesis and secretion of parathyroid hormone, effectively lowering its levels in the body.
Development Insights
Details
- Status
- Discontinued
- First Approved
- 1998-04-17
- Routes
- ORAL, INTRAVENOUS
- Dosage Forms
- CAPSULE, SOLUTION
ZEMPLAR Approval History
What ZEMPLAR Treats
2 indicationsZEMPLAR is approved for 2 conditions since its original approval in 1998. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Secondary Hyperparathyroidism
- Chronic Kidney Disease
ZEMPLAR Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to ZEMPLAR
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
49 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT04524702 results posted | STUDY00000996 NCI-2020-05417, Winship5079-20 | Ph 2 | completed | Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer |
| NCT04064827 | M11-617 | Ph 3 | terminated | A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) |
| NCT04054362 PINBALL | 012255 | Ph 2 | completed | Paricalcitol Addition to Chemotherapy in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma |
| NCT02754726 results posted | NAPPCG-EB 2015-001 | Ph 2 | completed | Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma |
| NCT02030860 | UPCC 23213 | Ph 1 | completed | A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer |
| NCT03520790 | 18-021 | Ph 1 | terminated | Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer |
| NCT02876211 PIERAID | PIERAID-2013 | Ph 4 | terminated | Paricalcitol Improves Anemia of Inflammation |
| NCT04617067 | CTRIAL-IE 19-33 2020-000073-24, CTRIAL-IE 19-33 | Ph 2 | completed | Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer |
| NCT01725113 ECRIP results posted | 12027 | Ph 4 | terminated | Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol |
| NCT02930902 | 2016-0378 NCI-2016-01937, 2016-0378 | Ph 1 | completed | Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery |
| NCT03331562 results posted | TGen 17-001 MISP# 56240 | Ph 2 | completed | A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer |
| NCT03883919 | 201905201 | Ph 1 | completed | Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy |
| NCT03300921 | UPCC 26217 | Ph 1 | terminated | A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer |
| NCT01506947 results posted | W12-645 | Ph 4 | completed | A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients |
| NCT01939977 PARIDOINAL results posted | ACA-SPAI-11-24 2013-001326-25 | Ph 4 | completed | Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation. |
| NCT02686827 BM4SIT | BM4SIT | Ph 2 | completed | DBPC-Dose-finding-trial of Vitamin D3 for SCIT in Birch Pollen Allergic Patients. |
| NCT01820767 SENPARIC | SENPARIC-2011-01 | Ph 3 | completed | Paricalcitol Over Inflammatory Parameters on Chronical Kidney Disease Patients |
| NCT00634582 results posted | IRB00004564 P30CA012197, CCCWFU-85107 | Ph 2 | terminated | Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases |
| NCT01197664 | IRB00013006 NCI-2011-02409, CCCWFU 54110 | Ph 1 | terminated | Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery |
| NCT01020487 results posted | M10-149 2010-019439-37 | Ph 3 | completed | Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children Aged 10-16 With Chronic Kidney Disease (CKD) |
| NCT01382212 results posted | M11-612 2013-002610-13 | Ph 3 | completed | A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis |
| NCT01436747 | 31-06-2011 | Ph 3 | completed | Efficacy and Safety of Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients |
| NCT00752102 VCOR results posted | Abbott #20128 | Ph 4 | completed | Vitamin D and Coronary Calcification Study |
| NCT00637897 | CDR0000583652 P30CA012197, CCCWFU-74307 | Ph 1 | completed | Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer |
| NCT01138475 ExtenD results posted | 2009-234 | Ph 3 | completed | Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery |
| NCT01393808 PROCEED | PROCEED 2011-001713-14 | Ph 2 | completed | Salt Intake and Antiproteinuric Effect of Paricalcitol in Type 2 Diabetes |
| NCT02282813 results posted | CTAP101-CL-3003 | Ph 3 | completed | Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002 |
| NCT01694160 | 2012/107 D 2012-000429-32 | Ph 3 | completed | Oral Paricalcitol in Renal Transplant Recipients for Reducing Albuminuria |
| NCT00599963 | CRE-2007.409-T CRE-2007.409-T | Ph 3 | withdrawn | Paricalcitol for the Treatment of Immunoglobulin A Nephropathy |
| NCT01265615 results posted | VDCRS03 | Ph 4 | completed | Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients |
| NCT02372695 MICROBUB | MICROBUB-2011-01 2011-002554-30 | Ph 4 | terminated | Effect of Paricalcitol Over Vessel Wall |
| NCT00823303 PACE results posted | 22095 | Ph 4 | completed | Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT) |
| NCT01768351 | PCX1234 paranemia | Ph 4 | completed | Paricalcitol Effect on Anemia in CKD |
| NCT01012414 VINCA-CKD results posted | 09C.110 | Ph 3 | terminated | Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease |
| NCT01003275 results posted | 35501-D | Ph 2 | completed | Metabolic Effects of Paricalcitol |
| NCT01204528 SOLID | VDRA | Ph 2, Ph 3 | completed | Vitamin-D Receptor Activation (VDRA) in Chronic Kidney Disease |
| NCT01341782 results posted | M11-517 | Ph 3 | completed | Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism |
| NCT01163162 Paricalcitol results posted | 1003-15 | Ph 4 | completed | The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate |
| NCT00497146 PRIMO results posted | M10-030 2007-001689-34 | Ph 3 | completed | The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4 |
| NCT01220050 APPLE | APPLE 2008-006380-36 | Ph 2 | completed | Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism |
| NCT00977080 IMPACT SHPT results posted | M10-967 2009-011378-14 | Ph 4 | completed | Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D |
| NCT01331317 | 2009-011255-44 | Ph 4 | completed | Effect of a Vitamin D Analogue vs Placebo on p-NT-proBNP in Patients With Type 1 DM and Diabetic Nephropathy |
| NCT01071070 results posted | M06-823 | Ph 3 | completed | Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease |
| NCT01136564 | EBP-TL-2010 2009-017619-14 | Ph 2 | completed | Reno- and Vascular Protective Effect of a Vitamin-D-analogue in Moderate to Severe Chronic Kidney Disease |
| NCT00664430 results posted | W10-131 | Ph 4 | terminated | Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects |
| NCT00667576 results posted | M10-309 | Ph 2 | completed | Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis |
| NCT00990704 results posted | M11-609 | Ph 2 | completed | Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism |
| NCT00701805 results posted | M10-312 | Ph 2 | completed | Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD) |
| NCT00958451 | CK0023 | Ph 4 | completed | Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ZEMPLAR FDA Label Details
Indications & Usage
FDA Label (PDF)ZEMPLAR is indicated for the treatment of Secondary Hyperparathyroidism; Chronic Kidney Disease.
Track ZEMPLAR with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment